EP1100917A1 - Genes d'ehrlichia granulocyte et leurs utilisations - Google Patents

Genes d'ehrlichia granulocyte et leurs utilisations

Info

Publication number
EP1100917A1
EP1100917A1 EP98955088A EP98955088A EP1100917A1 EP 1100917 A1 EP1100917 A1 EP 1100917A1 EP 98955088 A EP98955088 A EP 98955088A EP 98955088 A EP98955088 A EP 98955088A EP 1100917 A1 EP1100917 A1 EP 1100917A1
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
bov
wic
slov2
swed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98955088A
Other languages
German (de)
English (en)
Inventor
Cheryl I. Murphy
Robert F. Massung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aquila Biopharmaceuticals Inc
Centers of Disease Control and Prevention CDC
Original Assignee
Aquila Biopharmaceuticals Inc
Centers of Disease Control and Prevention CDC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquila Biopharmaceuticals Inc, Centers of Disease Control and Prevention CDC filed Critical Aquila Biopharmaceuticals Inc
Publication of EP1100917A1 publication Critical patent/EP1100917A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates, in general, to granulocytic Ehrlichia (GE) proteins.
  • the present invention relates to nucleic acid molecules coding for WI 1 , WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 proteins; purified WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BO
  • Granulocytic ehrlichiosis is an acute, potentially fatal tick-borne infection.
  • the causative agent, granulocytic ehrlichia (GE) has been identified by the polymerase chain reaction (PCR) using universal primers for eubacterial 16S ribosomal RNA (rRNA) to amplify the DNA of infected patients' blood (Chen et al, J. Clin. Micro. 52:589-595 (1994)).
  • rRNA ribosomal RNA
  • Comparison of the 16S rRNA gene sequence of GE to other known 16S rDNA sequences revealed a nearly identical match to the 16S genes of Ehrlichia phagocy tophi la and Ehrlichia equi (Chen et al. 1994).
  • Ehrlichia canis and Ehrlichia sennetsu groups Two other groups of Ehrlichia species have also been categorized according to their 16S rRNA gene sequences, the Ehrlichia canis and Ehrlichia sennetsu groups.
  • the E. canis and E. sennetsii species predominantly infect mononuclear phagocytes (Dumler et al, N. Eng. J. Med. 325: 1 109-1110 (1991)), whereas members of the E. phagocytophila group including G ⁇ are tropic for granulocytes (Ristic et al, in Bergey's Manual of Systemic Bacteriology, Kreig et al, eds., (1984), pp. 704- 709).
  • the present invention describes G ⁇ specific genes encoding thirteen proteins (WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SW ⁇ D, BOV, ⁇ Q, SLOVl, and SLOV2) which can be used as diagnostic reagents and vaccines.
  • the invention provides isolated nucleic acid molecules coding for polypeptides comprising amino acid sequences corresponding to WIl, WI2, WI3, WI4, WIC, NYl , NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 proteins.
  • the invention further provides purified polypeptides comprising amino acid sequences corresponding to WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 proteins.
  • the invention also provides nucleic acid probes for the specific detection of the presence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 proteins or polypeptides in a sample.
  • the invention further provides a method of detecting nucleic acid encoding WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 protein in a sample.
  • the invention also provides a kit for detecting the presence of nucleic acid encoding WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein in a sample.
  • the invention further provides a recombinant nucleic acid molecule comprising, 5' to 3', a promoter effective to initiate transcription in a host cell and the above-described isolated nucleic acid molecule.
  • the invention also provides a recombinant nucleic acid molecule comprising a vector and the above-described isolated nucleic acid molecule.
  • the invention further provides a recombinant nucleic acid molecule comprising a sequence complimentary to an RNA sequence encoding an amino acid sequence corresponding to the above-described polypeptide.
  • the invention also provides a cell that contains the above-described recombinant nucleic acid molecule.
  • the invention further provides a non-human organism that contains the above- described recombinant nucleic acid molecule.
  • the invention also provides an antibody having binding affinity specifically to a WIl, WI2, WI3. WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein or polypeptide.
  • the invention further provides a method of detecting WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein or polypeptide in a sample.
  • the invention also provides a method of measuring the amount of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein or polypeptide in a sample.
  • the invention further provides a method of detecting antibodies having binding affinity specifically to a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOV 1 , or SLOV2 protein or polypeptide.
  • the invention further provides a diagnostic kit comprising a first container means containing the above-described antibody, and a second container means containing a conjugate comprising a binding partner of the monoclonal antibody and a label.
  • the invention also provides a hybridoma which produces the above-described monoclonal antibody.
  • the invention further provides diagnostic methods for ehrlichiosis. More specifically, the invention further provides a method for identifying granulocytic Ehrlichia in an animal comprising analyzing tissue or body fluid from the animal for a WIl. WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid, protein, polysaccharide, or antibody.
  • the invention also provides methods for therapeutic uses involving all or part of the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid or protein.
  • the invention further provides a vaccine comprising a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein or nucleic acid together with a pharmaceutically acceptable diluent, carrier, or excipient, wherein the protein or nucleic acid is present in an amount effective to elicit a beneficial immune response in an animal to the protein.
  • a vaccine comprising a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein or nucleic acid together with a pharmaceutically acceptable diluent, carrier, or excipient, wherein the protein or nucleic acid is present in an amount effective to elicit a beneficial immune response in an animal to the protein.
  • the invention also provides a method of preventing or inhibiting ehrlichiosis in an animal comprising administering to the animal the above-described vaccine.
  • rDNA recombinant DNA
  • isolated nucleic acid molecule refers to a polymer of nucleotides, and includes but should not be limited to DNA and RNA.
  • Recombinant DNA Any DNA molecule formed by joining DNA segments from different sources and produced using recombinant DNA technology (i.e., molecular genetic engineering).
  • a DNA segment refers to a molecule comprising a linear stretch of nucleotides wherein the nucleotides are present in a sequence that can encode, through the genetic code, a molecule comprising a linear sequence of amino acid residues that is referred to as a protein, a protein fragment or a polypeptide.
  • a DNA sequence related to a single polypeptide chain or protein, and as used herein includes the 5' and 3' untranslated ends.
  • the polypeptide can be encoded by a full-length sequence or any portion of the coding sequence, so long as the functional activity of the protein is retained.
  • cDNA Complementary DNA
  • mRNA messenger RNA
  • Structural Gene A DNA sequence that is transcribed into mRNA that is then translated into a sequence of amino acids characteristic of a specific polypeptide. Open Reading Frame (orf). The property of some nucleic acid sequences to encode for more than one peptide within the same sequence, which is possible because these sequences contain a series of triplets coding for amino acids without any termination codons interrupting the relevant reading frames.
  • restriction endonuclease also restriction enzyme
  • a restriction endonuclease is an enzyme that has the capacity to recognize a specific base sequence (usually 4, 5, or 6 base pairs in length) in a DNA molecule, and to cleave the DNA molecule at every place where this sequence appears.
  • EcoRI recognizes the base sequence GAATTC/CTTAAG.
  • Restriction Fragment The DNA molecules produced by digestion with a restriction endonuclease are referred to as restriction fragments. Any given genome can be digested by a particular restriction endonuclease into a discrete set of restriction fragments.
  • DNA fragments of genomes can be visualized successfully. However, most genomes, including the human genome, contain far too many DNA sequences to produce a simple pattern of restriction fragments. For example, the human genome is digested into approximately 1,000,000 different DNA fragments by EcoRI. In order to visualize a small subset of these fragments, a methodology referred to as the Southern hybridization procedure can be applied.
  • Southern Transfer Procedure The purpose of the Southern transfer procedure (also referred to as blotting) is to physically transfer DNA fractionated by agarose gel electrophoresis onto a nitrocellulose filter paper or another appropriate surface or method, while retaining the relative positions of DNA fragments resulting from the fractionation procedure.
  • the methodology used to accomplish the transfer from agarose gel to nitrocellulose involves drawing the DNA from the gel into the nitrocellulose paper by capillary action or electrophonetic transfer.
  • Nucleic Acid Hybridization Nucleic acid hybridization depends on the principle that two single-stranded nucleic acid molecules that have complementary base sequences will reform the thermodynamically favored double-stranded structure if they are mixed under the proper conditions.
  • the double-stranded structure will be formed between two complementary single-stranded nucleic acids even if one is immobilized on a nitrocellulose filter as by the Southern hybridization transfer procedures.
  • Southern hybridization procedure the latter situation occurs.
  • the DNA of the individual to be tested is digested with a restriction endonuclease, fractionated by agarose gel electrophoresis, converted to the single-stranded form, and transferred to nitrocellulose paper, making it available for reannealing to the hybridization probe. Examples of hybridization conditions can be found in Ausubel, F.M. et al, Current Protocols in Molecular Biology, John Wily & Sons, Inc., New York, NY (1989).
  • a nitrocellulose filter is incubated overnight at 68°C with labeled probe in a solution containing 50% formamide, high salt (either 5X SSC [20X: 3M NaCl/0.3M trisodium citrate] or 5X SSPE [20X: 3.6M NaCl/0.2M NaH 2 PO 4 /0.02M EDTA, pH 7.7]), 5X Denhardt's solution, 1% SDS, and 100 ⁇ g/ml denatured salmon sperm DNA. This is followed by several washes in 0.2X SSC/0.1% SDS al a temperature selected based on the desired stringency: room temperature (low stringency), 42°C (moderate stringency) or 68°C (high stringency). The temperature selected is determined based on the melting temperature (Tm) of the DNA hybrid.
  • Tm melting temperature
  • Hybridization Probe To visualize a particular DNA sequence in the Southern hybridization procedure, a labeled DNA molecule or hybridization probe is reacted to the fractionated DNA bound to the nitrocellulose filter. The areas on the filter that carry
  • DNA sequences complementary to the labeled DNA probe become labeled themselves as a consequence of the reannealing reaction.
  • the areas of the filter that exhibit such labeling are visualized.
  • the hybridization probe is generally produced by molecular cloning of a specific DNA sequence.
  • Oligonucleotide or Oligomer A molecule comprised of two or more deoxyribonucleotides or ribonucleotides, preferably more than three. Its exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. An oligonucleotide can be derived synthetically or by cloning.
  • Sequence Amplification A method for generating large amounts of a target sequence.
  • one or more amplification primers are annealed to a nucleic acid sequence.
  • sequences found adjacent to, or in between the primers are amplified.
  • Amplification Primer An oligonucleotide which is capable of annealing adjacent to a target sequence and serving as an initiation point for DNA synthesis when placed under conditions in which synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated.
  • Vector A plasmid or phage DNA or other DNA sequence into which DNA can be inserted to be cloned.
  • the vector can replicate autonomously in a host cell, and can be further characterized by one or a small number of endonuclease recognition sites al which such DNA sequences can be cut in a determinable fashion and into which DNA can be inserted.
  • the vector can further contain a marker suitable for use in the identification of cells transformed with the vector. Markers, for example, are tetracycline resistance or ampicillin resistance. The words "cloning vehicle” are sometimes used for "vector.”
  • Expression is the process by which a structural gene produces a polypeptide. It involves transcription of the gene into mRNA, and the translation of such mRNA into polypeptide(s). Expression Vector.
  • the cloned gene is usually placed under the control of (i.e., operably linked to) certain control sequences such as promoter sequences.
  • Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host and can additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.
  • a functional derivative of a sequence is a molecule that possesses a biological activity (either functional or structural) that is substantially similar to a biological activity of the protein or nucleic acid sequence.
  • a functional derivative of a protein can contain post-translational modifications such as covalently linked carbohydrate, depending on the necessity of such modifications for the performance of a specific function.
  • the term "functional derivative” is intended to include the fragments, segments, variants, analogs, or chemical derivatives of a molecule.
  • a molecule is said to be a chemical derivative of another molecule when it contains additional chemical moieties not normally a part of the molecule.
  • moieties can improve the molecule's solubility, absorption, biological half life, and the like.
  • the moieties can alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, and the like.
  • Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980). Procedures for coupling such moieties to a molecule are well known in the art.
  • Variant A variant of a protein or nucleic acid is meant to refer to a molecule substantially similar in structure and biological activity to either the protein or nucleic acid.
  • two molecules possess a common activity and can substitute for each other they arc considered variants as that term is used herein even if the composition or secondary, tertiary, or quaternary structure of one of the molecules is not identical to that found in the other, or if the amino acid or nucleotide sequence is not identical.
  • Allelc An allele is an alternative form of a gene occupying a given locus on the chromosome.
  • a mutation is any detectable change in the genetic material which can be transmitted to daughter cells and possibly even to succeeding generations giving rise to mutant cells or mutant individuals. If the descendants of a mutant cell give rise only to somatic cells in multicellular organisms, a mutant spot or area of cells arises. Mutations in the germ line of sexually reproducing organisms can be transmitted by the gametes to the next generation resulting in an individual with the new mutant condition in both its somatic and germ cells.
  • a mutation can be any (or a combination of) detectable, unnatural change affecting the chemical or physical constitution, mutability, replication, phenotypic function, or recombination of one or more deoxyribonucleotides; nucleotides can be added, deleted, substituted for, inverted, or transposed to new positions with and without inversion. Mutations can occur spontaneously and can be induced experimentally by application of mutagens. A mutant variation of a nucleic acid molecule results from a mutation. A mutant polypeptide can result from a mutant nucleic acid molecule.
  • a species is a group of actually or potentially interbreeding natural populations.
  • a species variation within a nucleic acid molecule or protein is a change in the nucleic acid or amino acid sequence that occurs among species and can be determined by DNA sequencing of the molecule in question.
  • Purified A purified protein or nucleic acid is a protein or nucleic acid that has been separated from a cellular component. Purified proteins or nucleic acids have been purified to a level of purity not found in nature. Brief Description of the Figures
  • FIGURE 1 is a diagrammatic representation of the GE160 gene (S2 clone) showing the approximate location of the primer sets used for PCR amplification using DNA extracted from the blood of infected animals including humans.
  • Thin line DNA sequence; Box: coding region with nucleotide numbering shown at the start and stop codon based on the S2 clone.
  • FIGURE 2 shows the alignment of the nucleotide sequences derived from the representative clones of the invention WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2.
  • S2 GE160 is designated as usg3
  • WIC is designated as widog
  • EQ is designated as equi
  • BOV is designated as swedbovine.
  • FIGURE 3 shows the DNA sequence of representative clone WIC (SEQ ID NO:l).
  • FIGURE 4 shows the DNA sequence of representative clone SWED (SEQ ID NO:2).
  • FIGURE 5 shows the DNA sequence of representative clone EQ (SEQ ID NO:3).
  • FIGURE 6 shows the DNA sequence of representative clone BOV (SEQ ID NO:3).
  • FIGURE 7 shows the DNA sequence of representative clone WIl (SEQ ID NO:5).
  • FIGURE 8 shows the DNA sequence of representative clone WI2 (SEQ ID NO:6).
  • FIGURE 9 shows the DNA sequence of representative clone WI3 (SEQ ID NO:7).
  • FIGURE 10 shows the DNA sequence of representative clone WI4 (SEQ ID NO:8).
  • FIGURE 11 shows the DNA sequence of representative clone NYl (SEQ ID NO:9).
  • FIGURE 12 shows the DNA sequence of representative clone NY2 (SEQ ID NO: 10).
  • FIGURE 13 shows the DNA sequence of representative clone NY3 (SEQ ID NO: 11).
  • FIGURE 14 shows the DNA sequence of representative clone SLOVl (SEQ ID NO: 12).
  • FIGURE 15 shows the DNA sequence of representative clone SLOV2 (SEQ ID NO: 12).
  • FIGURE 16 shows the amino acid sequence of representative clone WIC (SEQ ID NO: 14).
  • FIGURE 17 shows the amino acid sequence of representative clone SWED (SEQ ID NO: 15).
  • FIGURE 18 shows the amino acid sequence of representative clone EQ (SEQ ID NO: 15).
  • FIGURE 19 shows the amino acid sequence of representative clone BOV (SEQ ID NO: 17).
  • FIGURE 20 shows the amino acid sequence of representative clone WIl (SEQ ID NO: 18).
  • FIGURE 21 shows the amino acid sequence of representative clone WI2 (SEQ ID NO: 19).
  • FIGURE 22 shows the amino acid sequence of representative clone WI3 (SEQ ID NO:20).
  • FIGURE 23 shows the amino acid sequence of representative clone WI4 (SEQ ID NO:20).
  • FIGURE 24 shows the amino acid sequence of representative clone NYl (SEQ ID NO:22).
  • FIGURE 25 shows the amino acid sequence of representative clone NY2 (SEQ ID NO:23).
  • FIGURE 26 shows the amino acid sequence of representative clone NY3 (SEQ ID NO:24).
  • FIGURE 27 shows the amino acid sequence of representative clone SLOVl (SEQ ID NO:25).
  • FIGURE 28 shows the amino acid sequence of representative clone SLOV2 (SEQ ID NO:25).
  • FIGURE 29 shows the alignment of the deduced amino acid sequence corresponding to the representative clones of this invention WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2.
  • S2 GE160 is designated as usg3
  • WIC is designated as widog
  • EQ is designated as equi
  • BOV is designated as swedbovine.
  • SWED, BOV, EQ, SLOVl, or SLOV2 Polypeptide or Antibody in a Sample IX. A Diagnostic Kit Comprising WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 Protein or Antibody; X. Diagnostic Screening; and
  • the present invention relates to isolated amino acid molecules comprising:
  • the isolated nucleic acid molecule comprises a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleotide sequence corresponding to SEQ ID NOS: 5, 6, 7, 8, 1, 9, 10, 11, 2, 4, 3, 12 or 13.
  • the isolated nucleic acid molecule comprises the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleotide sequence present in SEQ ID NOS: 5, 6, 7, 8, 1, 9, 10, 1 1, 2, 4, 3, 12, and 13 respectively.
  • the isolated nucleic acid molecule encodes the WIl, WI2, WI3, WI4, WIC, NYl. NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 amino acid sequence present in SEQ ID NOS: 18, 19, 20, 21, 14, 22, 23, 24, 15, 17, 16, 25, and 26, respectively.
  • nucleic acid sequences depicted in SEQ ID NOS: 5, 6, 7, 8, 1, 9, 10, 11, 2, 4, 3, 12 or 13 can be altered by substitutions, additions or deletions that provide for functionally equivalent molecules.
  • SEQ ID NOS: 18, 19, 20, 21 , 14, 22, 23, 24, 15, 17, 16, 25, and 26 can be used in the practice of the present invention.
  • nucleotide sequences comprising all or portions of WIl , WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 nucleic acid depicted in SEQ ID NOS: 5, 6, 78, 1, 9, 10, 11, 2, 4, 3, 12, or 13 respectively which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence.
  • nucleic acid sequence can comprise a nucleotide sequence which results from the addition, deletion or substitution of at least one nucleotide to the 5'-end and/or the 3'-end of the nucleic acid formula shown in SEQ ID NOS: 5, 6, 7, 8, 1, 9, 10, 11, 2, 4, 3, 12, and 13 or a derivative thereof.
  • Any nucleotide or polynucleotide can be used in this regard, provided that its addition, deletion or substitution does not substantially alter the amino acid sequence of SEQ ID NOS: 18. 19. 20. 21, 14. 22, 23, 24, 15, 17, 16, 25, and 26, which is encoded by the nucleotide sequence.
  • the nucleic acid molecule of the present invention can, as necessary, have restriction endonuclease recognition sites added to its 5'-end and/or 3'-end. All variations of the nucleotide sequence of the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 gene and lragments thereof permitted by the genetic code are, therefore, included in this invention. Further, it is possible to delete codons or to substitute one or more codons by codons other than degenerate codons to produce a structurally modified polypeptide, but one which has substantially the same utility or activity of the polypeptide produced by the unmodified nucleic acid molecule. As recognized in the art. the two polypeptides are functionally equivalent, as are the two nucleic acid molecules which give rise to their production, even though the differences between the nucleic acid molecules are not related to degeneracy of the genetic code.
  • nucleic acid molecules coding for polypeptides having amino acid sequences corresponding to WIl, WI2, WI3. WI4, WIC, NYl, NY2, NY3, SWED, BOV. EQ, SLOVl, and SLOV2 are provided.
  • the nucleic acid molecule can be isolated from a biological sample (preferably of mammalian or tick origin) containing GE RNA or DNA.
  • the nucleic acid molecule can be isolated from a biological sample containing GE RNA using the techniques of cDNA cloning and subtractive hybridization.
  • the nucleic acid molecule can also be isolated from a cDNA library using a homologous probe.
  • the nucleic acid molecule can be isolated from a biological sample containing genomic DNA or from a genomic library.
  • suitable biological samples include, but are not limited to, whole organisms, organs, tissues, blood and cells. The method of obtaining the biological sample will vary depending upon the nature of the sample.
  • the isolated nucleic acid molecule is also intended to include allelic variations, so long as the sequence is a functional derivative of the WIl, WI2, WI3, WI4, WIC, NYl, NY2. NY3.
  • SWED. BOV, EQ, SLOVl, and SLOV2 coding sequence When a WIl, WI2. WI3. WI4, WIC. NYl, NY2, NY3.
  • SWED, BOV, EQ, SLOVl, or SLOV2 allcle does not encode the identical sequence to that found in SEQ ID NOS: 5, 6, 7, 8, 1, 9, 10, 11. 2, 4, 3, 12.
  • WIl , WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ. SLOVl, or SLOV2 using the same techniques used herein, and especially PCR techniques to amplify the appropriate gene with primers based on the sequences disclosed herein.
  • organisms other than GE will also contain WIl , WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 genes.
  • the invention is intended to include, but not be limited to WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ.
  • SLOV l and SLOV2 nucleic acid molecules isolated from the above-described organisms.
  • infected eukaryotes may contain the WIl, WI2, WI3, WI4, WIC, NYl. NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 genes.
  • Isolated nucleic acid molecules of the present invention are also meant to include those chemically synthesized.
  • a nucleic acid molecule with the nucleotide sequence which codes for the expression product of WIl, WI2. WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOV l. or SLOV2 gene can be designed and. if necessary, divided into appropriate smaller fragments. Then an oligomer which corresponds to the nucleic acid molecule, or to each of the divided fragments, can be synthesized.
  • Such synthetic oligonucleotides can be prepared, for example, by the triester method of Matteucci et al, J. Am. Chem. Soc. 705:3185-3191 (1981) or by using an automated DNA synthesizer.
  • An oligonucleotide can be derived synthetically or by cloning. If necessary, the 5'-ends of the oligomers can be phosphorylated using T4 polynucleotide kinase. Kinasing of single strands prior to annealing or for labeling can be achieved using an excess of the enzyme. If kinasing is for the labeling of probe, the ATP can contain high specific activity radioisotopes. Then, the DNA oligomer can be subjected to annealing and ligation with T4 ligase or the like.
  • the present invention relates to a purified polypeptide (preferably, substantially pure) having an amino acid sequence corresponding to the polypeptide sequence encoded by the nucleic acid sequence corresponding to WIl, WI2, WI3, WI4, WIC, NYl. NY2, NY3, SWED. BOV, EQ, SLOVl, or SLOV2 or a functional derivative thereof or mutant or species variation thereof, or at least six amino acids thereof (preferably, at least 10, 15, 20, 25 or 50 contiguous amino acids thereof).
  • the invention relates to WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 epitopes.
  • the epitope of these polypeptides is an immunogenic or antigenic epitope.
  • An immunogenic epitope is that part of the protein which elicits an antibody response when the whole protein is the immunogen.
  • An antigenic epitope is a fragment of the protein which can elicit an antibody response. Methods of selecting antigenic epitope fragments are well known in the art. (Sutcliffe et al, Science 219:660-666 (1983)).
  • Antigenic epitope-bearing peptides and polypeptides of the invention are useful to raise an immune response that specifically recognizes the polypeptides.
  • Antigenic epitope-bearing peptides and polypeptides of the invention comprise at least 7 amino acids (preferably, 9, 10, 12, 15, or 20 amino acids) of the proteins of the invention.
  • Amino acid sequence variants of WIl, WI2, WI3. WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 can be prepared by mutations in the DNA.
  • Such variants include, for example, deletions from, or insertions or substitutions of. residues within the amino acid sequence of the peptide encoded by SEQ ID NOS: 18, 19, 20, 21, 14, 22, 23, 24, 15, 17, 16, 25, or 26. Any combination of deletion, insertion, and substitution can also be made to arrive at the final construct, provided that the final construct possesses the desired activity.
  • the mutation per se need not be predetermined.
  • random mutagenesis can be conducted at the target codon or region and the expressed WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3.
  • SWED, BOV, EQ, SLOVl, and SLOV2 variants screened for the optimal combination of desired activity.
  • Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, site-specific mutagenesis.
  • Preparation of a WI l, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 variant in accordance herewith is preferably achieved by site-specific mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of the protein.
  • Site-specific mutagenesis allows the production of WIl, WI2. WI3. WI4, WIC, NYl, NY2, NY3, SWED. BOV, EQ, SLOVl, and SLOV2 variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation.
  • site-specific mutagenesis is well known in the art, as exemplified by publications such as Adelman et al, DNA 2: 183 (1983) and Ausubel et al. "Current Protocols in Molecular Biology", J. Wiley & Sons, New York, NY, 1996.
  • the site-specific mutagenesis technique can employ a phage vector that exists in both a single-stranded and double-stranded form.
  • Typical vectors useful in site-directed mutagenesis include vectors such as the M 13 phage, for example, as disclosed by Messing et al, Third Cleveland Symposium on Macromolecules and Recombinant DNA, A.
  • phage are readily commercially available and their use is generally well known to those skilled in the art.
  • plasmid vectors that contain a single-stranded phage origin of replication can be employed to obtain single-stranded DNA.
  • site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant protein.
  • An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea et al, Proc. Natl. Acad. Sci. (USA) 75:5765 (1978).
  • This primer is then annealed with the single-stranded protein-sequence-containing vector, and subjected to DNA-polymerizing enzymes such as E. coli polymerase I Klenow fragment, to complete the synthesis of the mutation-bearing strand.
  • DNA-polymerizing enzymes such as E. coli polymerase I Klenow fragment
  • This heteroduplex vector is then used to transform appropriate cells and clones are selected that include recombinant vectors bearing the mutated sequence arrangement. After such a clone is selected, the mutated protein region can be removed and placed in an appropriate vector for protein production, generally an expression vector of the type that can be employed for transformation of an appropriate host.
  • Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably 1 to 10 residues, and typically are contiguous.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions of from one residue to polypeptides of essentially unrestricted length, as well as intrasequence insertions of single or multiple amino acid residues.
  • Intrasequence insertions i.e., insertions within the complete WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 sequence
  • the third group of variants are those in which at least one amino acid residue in the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 molecule, and preferably, only one, has been removed and a different residue inserted in its place.
  • substitutions preferably are made in accordance with the following Table 1 when it is desired to modulate finely the characteristics of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2.
  • Table 1 Table 1
  • Substantial changes in functional or immunological identity are made by selecting substitutions that are less conservative than those in Table 1. i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
  • substitutions that in general are expected are those in which (a) glycine and/or proline is substituted by another amino acid or is deleted or inserted; (b) a hydrophilic residue, e.g., seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g., leucyl, isoleucyl, phenylalanyl, valyl, or alanyl; (c) a cysteine residue is substituted for (or by) any other residue; (d) a residue having an electropositive side chain, e.g., lysyl, arginyl, or hislidyl, is substituted for (or by) a residue having an electronegative charge, e.g., glutamyl or aspartyl; or (e) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having such a side chain, e.g
  • deletions and insertions, and substitutions are not expected to produce radical changes in the characteristics of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2.
  • a variant typically is made by site-specific mutagenesis of the native WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED.
  • BOV, EQ, SLOVl, or SLOV2 encoding-nucleic acid expression of the variant nucleic acid in recombinant cell culture, and, optionally, purification from the cell culture, for example, by immunoaffinity adsorption on a column (to absorb the variant by binding it to at least one remaining immune epitope).
  • the activity of the cell lysate or purified WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 molecule variant is then screened in a suitable screening assay for the desired characteristic.
  • a change in the immunological character of the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 molecule, such as affinity for a given antibody is measured by a competitive type immunoassay. Changes in immunomodulation activity are measured by the appropriate assay. Modifications of such protein properties as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation or the tendency to aggregate with carriers or into multimers are assayed by methods well known to the ordinarily skilled artisan.
  • the peptide is purified from tissues or cells which naturally produce the peptide.
  • the above-described isolated nucleic acid fragments can be used to express the WIl, WI2. WI3, WI4, WIC, NYl. NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein in any organism.
  • the samples of the present invention include cells, protein extracts or membrane extracts of cells, or biological fluids. The sample will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts used as the sample.
  • any prokaryotic (preferably, a granulocytic ehrlichia) organism can be used as a source for the peptide of the invention, as long as the source organism naturally contains such a peptide.
  • a eukaryotic organism infected with granulocytic ehrlichia can also be used as the source organism.
  • source organism refers to the original organism from which the amino acid sequence of the subunit is derived, regardless of the organism the subunit is expressed in and ultimately isolated from.
  • the present invention relates to a nucleic acid probe for the specific detection of the presence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid in a sample comprising the above- described nucleic acid molecules or at least a fragment thereof which binds under stringent conditions to WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid.
  • the present invention relates to an isolated nucleic acid probe consisting of 10 to 1000 nucleotides (preferably, 10 to 500, 10 to 100, 10 to 50, 10 to 35, 20 to 1000, 20 to 500, 20 to 100, 20 to 50, or 20 to 35) which hybridizes preferentially to RNA or DNA of granulocytic ehrlichia but not to RNA or DNA of non- granulocytic ehrlichia organisms (example, humans), wherein said nucleic acid probe is or is complementary to a nucleotide sequence consisting of at least 10 consecutive nucleotides (preferably, 15, 20, 25, or 30) from the nucleic acid molecule comprising a polynucleotide sequence at least 90% identical to a sequence selected from:
  • the nucleic acid probe can be used to probe an appropriate chromosomal or cDNA library by usual hybridization methods to obtain another nucleic acid molecule of the present invention.
  • a chromosomal DNA or cDNA library can be prepared from appropriate cells according to recognized methods in the art (cf. Molecular Cloning: A Laboratoiy Manual, 2nd edition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989). In the alternative, chemical synthesis is carried out in order to obtain nucleic acid probes having nucleotide sequences which correspond to amino-terminal and carboxy- terminal portions of the amino acid sequence corresponding to the amino acid sequence of the peptide encoded by SEQ ID NOS: 5, 6, 7, 8, 1, 9, 10, 11, 2, 4, 3, 12, or 13.
  • the synthesized nucleic acid probes can be used as primers in a polymerase chain reaction (PCR) carried out in accordance with recognized PCR techniques, essentially according to PCR Protocols, A Guide to Methods and Applications, edited by Michael et al, Academic Press, 1990, utilizing the appropriate chromosomal, cDNA or cell line library to obtain the fragment of the present invention.
  • PCR polymerase chain reaction
  • the hybridization probes of the present invention can be labeled by standard labeling techniques such as with a radiolabel, enzyme label, fluorescent label, biotin-avidin label, chemiluminescence, and the like. After hybridization, the probes can be visualized using known methods.
  • the nucleic acid probes of the present invention include RNA, as well as DNA probes, such probes being generated using techniques known in the art.
  • a nucleic acid probe is immobilized on a solid support.
  • solid supports include, but are not limited to, plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, and acrylic resins, such as polyacrylamide and latex beads. Techniques for coupling nucleic acid probes to such solid supports are well known in the art.
  • test samples suitable for nucleic acid probing methods of the present invention include, for example, cells or nucleic acid extracts of cells, or biological fluids.
  • the sample used in the above-described methods will vary based on the assay format, the detection method and the nature of the tissues, cells or extracts to be assayed. Methods for preparing nucleic acid extracts of cells are well known in the art and can be readily adapted in order to obtain a sample which is compatible with the method utilized.
  • the present invention relates to a method of detecting the presence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid in a sample comprising a) contacting the sample with the above- described nucleic acid probe, under specific hybridization conditions such that hybridization occurs, and b) detecting the presence of the probe bound to the nucleic acid molecule.
  • the method of detecting the presence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid in a sample may comprise a) amplifying the nucleic acid in the sample with the nucleic acid probe wherein the amplification uses PCR techniques and b) detecting the presence of the amplified nucleic acid molecules.
  • the nucleic acid probe include but should not be limited to RNA samples from human tissue. V. A Kit for Detecting the Presence of WIl, WI2, WI3, W14, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 in a Sample
  • the present invention relates to a kit for detecting the presence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid in a sample comprising at least one container means having disposed therein the above-described nucleic acid probe.
  • the kit further comprises other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound nucleic acid probe.
  • detection reagents include, but are not limited to radiolabeUed probes, enzymatic labeled probes (horse radish peroxidase, alkaline phosphatase), and affinity labeled probes (biotin, avidin, or steptavidin).
  • a compartmentalized kit includes any kit in which reagents are contained in separate containers.
  • Such containers include small glass containers, plastic containers or strips of plastic or paper.
  • Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another.
  • Such containers will include a container which will accept the test sample, a container which contains the probe or primers used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, and the like), and containers which contain the reagents used to detect the hybridized probe, bound antibody, amplified product, or the like.
  • nucleic acid probes described in the present invention can readily be inco ⁇ orated into one of the established kit formats which are well known in the art.
  • the present invention relates to a recombinant DNA molecule comprising, 5' to 3', a promoter effective to initiate transcription in a host cell and the above-described nucleic acid molecules.
  • the present invention relates to a recombinant DNA molecule comprising a vector and an above- described nucleic acid molecule.
  • the present invention relates to a nucleic acid molecule comprising a transcriptional control region functional in a cell, a sequence complimentary to an RNA sequence encoding an amino acid sequence corresponding to the above- described polypeptide, and a transcriptional termination region functional in the cell.
  • the above-described molecules are isolated and/or purified DNA molecules.
  • the present invention relates to a cell or non-human organism that contains an above-described nucleic acid molecule.
  • the peptide is purified from cells which have been altered to express the peptide.
  • a cell is said to be "altered to express a desired peptide" when the cell, through genetic manipulation, is made to produce a protein which it normally does not produce or which the cell normally produces at low levels.
  • One skilled in the art can readily adapt procedures for introducing and expressing either genomic, cDNA, or synthetic sequences into either eukaryotic or prokaryotic cells.
  • a nucleic acid molecule such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are “operably linked” to nucleotide sequences which encode the polypeptide.
  • An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed arc connected in such a way as to permit gene sequence expression.
  • regulatory regions needed for gene sequence expression can vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation.
  • promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal synthesis initiation.
  • Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.
  • the non-coding region 3' to the WI l, WI2, WI3, WI4, WIC. NYl, NY2, NY3, SWED, BOV, EQ. SLOVl, or SLOV2 coding sequence can be obtained by the above-described methods.
  • This region can be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation.
  • the transcriptional termination signals can be provided.
  • Two DNA sequences (such as a promoter region sequence and an WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 coding sequence) are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 coding sequence, or (3) interfere with the ability of the WIl, WI2, WI3, WI4, WIC, NYl, NY2, SWED, BOV, EQ, SLOVl , or SLOV2 coding sequence to be transcribed by the promoter region sequence.
  • a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence.
  • the present invention encompasses the expression of the WIl. WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 coding sequence (or a functional derivative thereof) in either prokaryotic or eukaryotic cells.
  • Prokaryotic hosts are, generally, the most efficient and convenient for the production of recombinant proteins and, therefore, are preferred for the expression of the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 coding sequence.
  • Prokaryotes most frequently are represented by various strains of E. coli.
  • plasmid vectors that contain replication sites and control sequences derived from a species compatible with the host can be used.
  • suitable plasmid vectors include pBR322, pUC18, pUC19, pUC118, pUC119 and the like;
  • suitable phage or bacteriophage vectors include ⁇ gtlO, ⁇ gtl l and the like;
  • suitable virus vectors include pMAM-neo, pKRC and the like.
  • the selected vector of the present invention has the capacity to replicate in the selected host cell.
  • prokaryotic hosts include bacteria such as E. coli, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, and the like. However, under such conditions, the peptide will not be glycosylated.
  • the prokaryotic host must be compatible with the replicon and control sequences in the expression plasmid.
  • WIl WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 in a prokaryotic cell, it is necessary to operably link the, WIl, WI2, WI3, WI4, WIC, NYl , NY2, NY3. SWED, BOV, EQ, SLOVl, or SLO .
  • V2 coding sequence to a functional prokaryotic promoter can be either constitutive or, more preferably, regulatable (i.e., inducible or derepressible).
  • constitutive promoters include the int promoter of bacteriophage ⁇ , the bla promoter of the ⁇ - lactamase gene sequence of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene sequence of pBR325, and the like.
  • inducible prokaryotic promoters include the major right and left promoters of bacteriophage ⁇ (P L and P R ), the trp, recA, lacZ, lad, and gal promoters of E.
  • subtilis (Gilman et al, Gene Sequence 32: 11-20 (1984)), the promoters of the bacteriophages of Bacillus (Gryczan, In: 777e Molecular Biology of the Bacilli, Academic Press, Inc., NY (1982)), and Streptomyces promoters (Ward et al, Mol. Gen. Genet. 20i:468-478 (1986)).
  • Prokaryotic promoters are reviewed by Glick (J. lnd. Microbiol. 7:277-282 (1987));
  • ribosome binding sites are disclosed, for example, by Gold et al. (Ann. Rev. Microbiol. i5:365-404 (1981)).
  • the selection of control sequences, expression vectors, transformation methods, and the like, are dependent on the type of host cell used to express the gene.
  • “cell”, “cell line”, and “cell culture” can be used interchangeably and all such designations include progeny.
  • the words “transformants” or “transformed cells” include the primary subject cell and cultures derived therefrom, without regard to the number of transfers.
  • progeny can not be precisely identical in DNA content, due to deliberate or inadvertent mutations. However, as defined, mutant progeny have the same functionality as that of the originally transformed cell.
  • Host cells which can be used in the expression systems of the present invention are not strictly limited, provided that they are suitable for use in the expression of the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 peptide of interest.
  • Suitable hosts include eukaryotic cells.
  • Preferred eukaryotic hosts include, for example, yeast, fungi, insect cells, mammalian cells either in vivo, or in tissue culture.
  • Preferred mammalian cells include HeLa cells, cells of fibroblast origin such as VERO or CHO-K1, or cells of lymphoid origin and their derivatives.
  • plant cells are also available as hosts, and control sequences compatible with plant cells are available, such as the cauliflower mosaic virus 35S and 19S, and nopaline synthase promoter and polyadenylation signal sequences.
  • Another preferred host is an insect cell, for example Drosophila larvae.
  • insect cells for example Drosophila larvae.
  • the Drosophila alcohol dehydrogenase promoter can be used, (Rubin, Science 240: 1453-1459 (1988)).
  • baculovirus vectors can be engineered to express large amounts of WIl, WI2. WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOV l, or SLOV2 in insect cells (Jasny, Science 238: 1653 (1987); Miller et al, In: Genetic Engineering (1986), Setlow, J.K., et al, eds., Plenum, Vol. 8, pp. 277-297).
  • Different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage) of proteins.
  • Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.
  • yeast gene sequence expression systems can be utilized which inco ⁇ orate promoter and termination elements from the actively expressed gene sequences coding for glycolytic enzymes. These enzymes are produced in large quantities when yeast are grown in mediums rich in glucose. Known glycolytic gene sequences can also provide very efficient transcriptional control signals.
  • Yeast provides substantial advantages in that it can also carry out post-translational peptide modifications.
  • Yeast recognizes leader sequences on cloned mammalian gene sequence products and secretes peptides bearing leader sequences (i.e., pre-peptides).
  • leader sequences on cloned mammalian gene sequence products and secretes peptides bearing leader sequences (i.e., pre-peptides).
  • pre-peptides i.e., pre-peptides.
  • WIl WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV. EQ, SLOVl, or SLOV2.
  • transcriptional and translational regulatory sequences can be employed, depending upon the nature of the host.
  • the transcriptional and translational regulatory signals can be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, where the regulatory signals are associated with a particular gene sequence which has a high level of expression.
  • promoters from mammalian expression products such as actin, collagen, myosin, and the like, can be employed.
  • Transcriptional initiation regulatory signals can be selected which allow for repression or activation, so that expression of the gene sequences can be modulated.
  • SWED, BOV, EQ, SLOVl, or SLOV2 in eukaryotic hosts requires the use of eukaryotic regulatory regions. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis.
  • Preferred eukaryotic promoters include, for example, the promoter of the mouse metallothionein I gene sequence (Hamer et al, J. Mol. Appl. Gen.
  • eukaryotic mRNA As is widely known, translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 coding sequence does not contain any intervening codons which are capable of encoding a methionine (i.e.. AUG).
  • codons results either in a formation of a fusion protein (if the AUG codon is in the same reading frame as the WI l , WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 coding sequence) or a frame-shift mutation (if the AUG codon is not in the same reading frame as the WIl, WI2. WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 coding sequence).
  • WIC, NYl, NY2. NY3, SWED, BOV, EQ. SLOVl, or SLOV2 nucleic acid molecule and an operably linked promoter can be introduced into a recipient prokaryotic or eukaryotic cell either as a non-replicating DNA (or RNA) molecule, which can either be a linear molecule or, more preferably, a closed covalent circular molecule. Since such molecules are incapable of autonomous replication, the expression of the gene can occur through the transient expression of the introduced sequence. Alternatively, permanent expression can occur through the integration of the introduced DNA sequence into the host chromosome.
  • a vector is employed which is capable of integrating the desired gene sequences into the host cell chromosome.
  • Cells which have stably integrated the introduced DNA into their chromosomes can be selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector.
  • the marker can provide for prototrophy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like.
  • the selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements can also be needed for optimal synthesis of single chain binding protein mRNA. These elements can include splice signals, as well as transcription promoters, enhancer signal sequences, and termination signals.
  • cDNA expression vectors incorporating such elements include those described by Okayama, Molec. Cell. Biol. i:280 (1983).
  • the introduced nucleic acid molecule will be inco ⁇ orated into a plasmid or viral vector capable of autonomous replication in the recipient host.
  • a plasmid or viral vector capable of autonomous replication in the recipient host.
  • Any of a wide variety of vectors can be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector can be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.
  • Preferred prokaryotic vectors include plasmids such as those capable of replication in E.
  • coli such as, for example, pBR322, Col ⁇ l, pSClOl , pACYC 184, ⁇ VX.
  • plasmids are, for example, disclosed by Sambrook (cf. Molecular Cloning: A Laboratory Manual, second edition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory. 1989).
  • Bacillus plasmids include pC194, pC221, pT127, and the like. Such plasmids are disclosed by Gryczan (In: The Molecular Biology of the Bacilli, Academic Press, NY (1982), pp. 307-329).
  • Suitable Streptomyces plasmids include pIJlOl (Kendall et al, J. Bacte ⁇ ol 769:4177-4183 (1987)), and streptomyces bactcriophages such as ⁇ C31 (Chater et al, In: Sixth International Symposium on Actinomycetales Biology, Akademiai Kaido, Budapest. Hungary (1986), pp. 45-54). Pseudomonas plasmids are reviewed by John et al. (Rev. Infect. Dis. 5:693-704 (1986)), and Izaki (Jpn. J. Bacteriol. 33:129-142 (1978)).
  • Preferred eukaryotic plasmids include, for example, BPV, vaccinia, SV40, 2-micron circle, and the like, or their derivatives.
  • Such plasmids are well known in the art (Botstein et al, Miami Wntr. Symp. 79:265-274 (1982); Broach, In: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p. 445-470 (1981); Broach, Cell 25:203-204 (1982); Bollon et al, J. Clin. Hematol Oncol 70:39-48 (1980); Maniatis, In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene Sequence Expression, Academic Press, NY, pp. 563-608 (1980)).
  • the DNA construct(s) can be introduced into an appropriate host cell by any of a variety of suitable means, i.e., transformation, transfection, conjugation, protoplast fusion, electroporation, particle gun technology, calcium phosphate-precipitation, direct microinjection, and the like.
  • recipient cells are grown in a selective medium, which selects for the growth of vector-containing cells.
  • Expression of the cloned gene molecule(s) results in the production of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2. This can take place in the transformed cells as such, or following the induction of these cells to differentiate (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like).
  • the present invention relates to an antibody having binding affinity specifically to a WIl, WI2, WI3, WI4, WIC, NY l, NY2, NY3, SWED, BOV, EQ,
  • SLOVl or SLOV2 polypeptide as described above or specifically to a WIl, WI2, WI3,
  • WI4 WIC, NY l, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 polypeptide binding fragment thereof.
  • An antibody binds specifically to a WIl, WI2, WI3, WI4, WIC, NYl,
  • WI2 WI3, WI4 WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 or to consensus sequences described herein corresponding to the amino- and/or carboxy-terminus regions shared by WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 would be chosen for use in methods which could include, but should not be limited to, the analysis of altered WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 expression in tissue containing WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2.
  • the WIl, WI2, WI3, WI4, WIC, NYl, NY2. NY3, SWED, BOV, EQ, SLOVl, or SLOV2 proteins, or proteins including the consensus sequences corresponding to the amino- and/or carboxy-terminus regions shared by the proteins of the present invention can be used in a variety of procedures and methods, such as for the generation of antibodies, for use in identifying pharmaceutical compositions, and for studying DNA/protein interaction.
  • the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 proteins, or proteins including the consensus sequences corresponding to the amino and/or carboxy terminus regions shared by the above listed proteins of the present invention can be used to produce antibodies or hybridomas.
  • One skilled in the art will recognize that if an antibody is desired, such a peptide would be generated as described herein and used as an immunogen.
  • the antibodies of the present invention include monoclonal and polyclonal antibodies, as well as fragments of these antibodies.
  • the invention further includes single chain antibodies.
  • Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab') 2 fragment; the Fab' fragments, Fab fragments, and Fv fragments.
  • Humanized antibodies can be produced, for example by replacing an immunogenic portion of an antibody with a corresponding, but non-immunogenic portion (i.e., chimeric antibodies) (Robinson et al, PCT Application No. PCT/US86/02269; Akira et al, European Patent No. 184,187; Taniguchi, European Patent No. 171,496; Morrison et al, European Patent No. 173,494; Neuberger et al., PCT Application WO 86/01533; Cabilly et al, European Patent No. 125,023; Better, et al, Science 240: 1041-1043 (1988): Liu et al, Proc. Natl. Acad. Sci.
  • Suitable "humanized” antibodies can be alternatively produced by CDR or CEA substitution (Jones et al, Nature 321:552-525 (1986); Verhoeyan et al, Science 239: 1534 (1988); Beidler et al, J. Immunol. 141:4053-4060 (1988)).
  • the present invention relates to a hybridoma which produces the above-described monoclonal antibody.
  • a hybridoma is an immortalized cell line which is capable of secreting a specific monoclonal antibody.
  • techniques for preparing monoclonal antibodies and hybridomas are well known in the art (Campbell. "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistiy and Molecular Biology.” Elsevier Science Publishers, Amsterdam, The Netherlands (1984); St. Groth et al, J. Immunol Methods 35:1-21 (1980)). Any animal (mouse, rabbit, and the like) which is known to produce antibodies can be immunized with the selected polypeptide. Methods for immunization are well known in the art.
  • Such methods include subcutaneous or interperitoneal injection of the polypeptide.
  • One skilled in the art will recognize that the amount of polypeptide used for immunization will vary based on the animal which is immunized, the antigenicity of the polypeptide and the site of injection.
  • the polypeptide can be modified or administered in an adjuvant in order to increase the peptide antigenicity.
  • Methods of increasing the antigenicity of a polypeptide are well known in the art. Such procedures include coupling the antigen with a heterologous protein (such as globulin or ⁇ -galactosidase) or through the inclusion of an adjuvant during immunization.
  • a heterologous protein such as globulin or ⁇ -galactosidase
  • spleen cells from the immunized animals are removed, fused with myeloma cells, and allowed to become monoclonal antibody producing hybridoma cells.
  • any one of a number of methods well known in the art can be used to identify the hybridoma cell which produces an antibody with the desired characteristics. These include screening the hybridomas with an ELISA assay, Western blot analysis, or radioimmunoassay (Lutz et al, Exp. Cell Res. 75:109-124 (1988)).
  • Hybridomas secreting the desired antibodies are cloned and the class and subclass is determined using procedures known in the art (Campbell, Monoclonal Antibody
  • antibody containing antisera is isolated from the immunized animal and is screened for the presence of antibodies with the desired specificity using one of the above-described procedures.
  • the above-described antibodies are detectably labeled.
  • Antibodies can be detectably labeled through the use of radioisotopes, affinity labels (such as biotin, avidin, and the like), enzymatic labels (such as horseradish peroxidase, alkaline phosphatase, and the like) fluorescent labels (such as FITC or rhodamine, and the like), paramagnetic atoms, and the like. Procedures for accomplishing such labeling are well-known in the art, for example, see (Sternberger et al, J. Histochem.
  • the labeled antibodies of the present invention can be used for in vitro, in vivo, and in situ assays to identify cells or tissues which express a specific peptide.
  • the above-described antibodies arc immobilized on a solid support.
  • solid supports include plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, acrylic resins and such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the art (Weir et al , "Handbook of Experimental Immunology” 4th Ed., Blackwell Scientific Publications, Oxford, England, Chapter 10 (1986); Jacoby et al, Meth. Enzym. 34 Academic Press, N.Y. (1974)).
  • the immobilized antibodies of the present invention can be used for in vitro, in vivo, and in situ assays as well as in immunochromatography.
  • the antipeptide peptides can be generated by replacing the basic amino acid residues found in the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED. BOV. EQ, SLOVl. and SLOV2 peptide sequence or consensus sequences described herein with acidic residues, while maintaining hydrophobic and uncharged polar groups.
  • lysine. arginine, and/or histidine residues are replaced with aspartic acid or glutamic acid and glutamic acid residues are replaced by lysine, arginine or histidine.
  • the present invention relates to a method of detecting a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 Polypeptide or Antibody in a Sample
  • the present invention relates to a method of detecting a
  • the methods comprise incubating a test sample with one or more of the antibodies of the present invention and assaying whether the antibody binds to the test sample. Altered levels of peptides WIl, WI2, WI3, WI4. WIC. NYl.
  • the present invention relates to a method of detecting a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 antibody in a sample, comprising: a) contacting the sample with an above-described WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 polypeptide, including the consensus sequence corresponding to the amino- and/or carboxy-terminus regions shared by WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2 polypeptide under conditions such that immunocomplexes form, and b) detecting the presence of the protein bound to the antibody or antibody bound
  • the methods comprise incubating a test sample with one or more of the proteins of the present invention and assaying whether the antibody binds to the test sample.
  • the presence of antibodies to WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl , or SLOV2 may indicate exposure to GE, the potential need for therapy of the affected individual, or GE contamination of a biological sample.
  • Conditions for incubating an antibody with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the antibody used in the assay.
  • any one of the commonly available immunological assay formats can readily be adapted to employ the antibodies of the present invention.
  • immunological assay formats such as radioimmunoassays, enzyme-linked immunosorbent assays, diffusion based Ouchterlony, or rocket immunofluorescent assays
  • Examples of such assays can be found in Chard, An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers. Amsterdam, The Netherlands (1986): Bullock et al, Techniques in Immitnocytochemistiy, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 ( 1985): Tijssen, Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands ( 1985).
  • the immunological assay test samples of the present invention include cells, protein or membrane extracts of cells, or biological fluids such as blood, serum, plasma, or urine.
  • the test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing protein extracts or membrane extracts of cells are well known in the art and can be readily be adapted in order to obtain a sample which is capable with the system utilized.
  • a Diagnostic Kit Comprising WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 Protein or Antibody
  • a kit is provided which contains all the necessary reagents to carry out the previously described methods of detection.
  • the kit can comprise: i) a first container means containing an above-described antibody, and ii) second container means containing a conjugate comprising a binding partner of the antibody and a label.
  • the kit can comprise: i) a first container means containing an above-described protein, and preferably, ii) second container means containing a conjugate comprising a binding partner of the protein and a label. More specifically, a diagnostic kit comprises WIl, WI2, WI3, WI4, WIC, NYl, NY2.
  • the kit further comprises one or more other containers comprising one or more of the following: wash reagents and reagents capable of detecting the presence of bound antibodies.
  • detection reagents include, but are not limited to, labeled secondary antibodies, or in the alternative, if the primary antibody is labeled, the chromophoric, enzymatic, or antibody binding reagents which are capable of reacting with the labeled antibody.
  • the compartmentalized kit can be as described above for nucleic acid probe kits.
  • the antibodies described in the present invention can readily be incorporated into one of the established kit formats which are well known in the art.
  • a pre- and post-symptomatic screening of an individual in need of such screening is now possible using DNA encoding the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein or fragment thereof, or a protein having consensus sequences corresponding to the amino and/or carboxy terminus regions shared by WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 of the invention.
  • the screening method of the invention allows a presymptomatic diagnosis of the presence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein or DNA in individuals, and thus an opinion concerning the likelihood that such individual would develop or has developed ehrlichiosis. Early diagnosis is desired to maximize appropriate timely intervention.
  • a tissue sample would be taken from an individual, and screened for (1) the presence of the WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 DNA coding sequence; (2) the presence of WIl, WI2, WI3, WI4, WIC, NY l, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 mRNA; (3) the presence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein; and/or (4) the presence of antibody to WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein.
  • a preferred method of detecting the presence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein and/or the presence of antibody to WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein comprises: a) contacting the sample with a polypeptide or antibody to a polypeptide having the amino acid sequence of WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 or a fragment thereof under conditions such that immunocomplexes form; and b) detecting the presence of the immunocomplexed antibody and polypeptide.
  • Individuals not infected with GE do not have WIl, WI2, WI3, WI4, WIC, NYl,
  • the screening and diagnostic methods of the invention do not require that the entire WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 coding sequence be used for the probe. Rather, it is only necessary to use a fragment or length of nucleic acid that is sufficient to detect the presence of the WIl, WI2, WI3, WI4, WIC, NY l, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid in a DNA preparation from an individual.
  • nucleic acid specific to GE can be by PCR techniques or hybridization techniques (cf. Molecular Cloning: A Laboratoiy Manual, 2nd edition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989; Eremeeva et al, J. Clin. Microbiol. i2;803-810 (1994) which describes differentiation among spotted fever group
  • the present invention relates to a vaccine comprising a WIl,
  • WIl, WI2, WI3, WI4, WIC, NYl , NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 protein, or a protein having consensus sequences corresponding to any shared amino- and/or carboxy- terminus region may be obtained as described above and using methods well known in the art.
  • An immunologically active fragment comprises an epitope-bearing portion of the protein.
  • the present invention relates to a composition comprising a WIl, WI2, WI3, WI4, WIC, NYl , NY2, NY3, SWED. BOV, EQ, SLOVl, or SLOV2 protein or fragment thereof, or a protein having consensus sequences corresponding to any shared amino- and/or carboxy-terminus regions and a carrier.
  • the present invention relates to a vaccine comprising a WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3.
  • SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid preferably, DNA
  • a fragment thereof preferably, a fragment encoding an immunologically active protein or peptide
  • nucleic acid coding for a polypeptide or a protein having consensus sequences corresponding to any shared amino and/or carboxy terminus regions together with a pharmaceutically acceptable diluent, carrier, or excipient.
  • the nucleic acid is present in an amount effective to elicit a beneficial immune response in an animal to GE.
  • SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid may be obtained as described above and using methods well known in the art.
  • An immunologically active fragment comprises an epitope-bearing portion of the nucleic acid.
  • the present invention relates to a composition
  • a composition comprising a WI l , WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, or SLOV2 nucleic acid (preferably, DNA) or fragment thereof (preferably, encoding an immunologically reactive protein or fragment - antigenic epitope) and a carrier.
  • the present invention relates to a method of producing an immune response which recognizes GE in a host comprising administering to the host the above-described composition.
  • the animal to be protected is selected from humans, horses, deer, cattle, pigs, sheep, dogs, and chickens. In a more preferred embodiment, the animal is a human or a dog.
  • the present invention relates to a method of preventing ehrlichiosis in an animal comprising administering to the animal the above-described vaccine, wherein the vaccine is administered in an amount effective to prevent or inhibit Ehrlichiosis.
  • the vaccine of the invention is used in an amount effective depending on the route of administration. Although intranasal, subcutaneous or intramuscular routes of administration are preferred, the vaccine of the present invention can also be administered by an oral, intraperitoneal or intravenous route.
  • the amounts to be administered for any particular treatment protocol can be readily determined without undue experimentation. Suitable amounts are within the range of 2 ⁇ g of the WIl, WI2.
  • vaccine formulations including antigen amounts, route of administration and addition of adjuvants can be found in Kensil, Therapeutic Drug Carrier Systems 73:1-55 (1996), Livingston et al, Vaccine 72:1275 (1994), and Powell et al, AIDS RES, Human Retroviruses 70:5105 (1994).
  • the vaccine of the present invention may be employed in such forms as capsules, liquid solutions, suspensions or elixirs for oral administration, or sterile liquid forms such as solutions or suspensions.
  • Any inert carrier is preferably used, such as saline, phosphate- buffered saline, or any such carrier in which the vaccine has suitable solubility properties.
  • the vaccines may be in the form of single dose preparations or in multi-dose flasks which can be used for mass vaccination programs. Reference is made to Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, Osol (ed.) (1980); and New Trends and Developments in Vaccines, Voller et al. (eds.), University Park Press, Baltimore, MD (1978), for methods of preparing and using vaccines.
  • the vaccines of the present invention may further comprise adjuvants which enhance production of antibodies and immune cells.
  • adjuvants include, but are not limited to, various oil formulations such as Freund's complete adjuvant (CFA), the dipeptide known as MDP, saponins (e.g., QS-21, U.S. Patent No. 5,047,540), aluminum hydroxide, or lymphatic cytokines.
  • CFA Freund's complete adjuvant
  • MDP dipeptide known as MDP
  • saponins e.g., QS-21, U.S. Patent No. 5,047,540
  • aluminum hydroxide e.g., cytokines
  • lymphatic cytokines cytokines.
  • Freund's adjuvant is an emulsion of mineral oil and water which is mixed with the immunogenic substance. Although Freund's adjuvant is powerful, it is usually not administered to humans. Instead, the adjuvant alum (aluminum hydroxide) may be used for administration to a
  • Protocol A Cultivation of GE in HL60 cells
  • the GE-infectcd HL60 cell line, USG3. is obtained by co-culturing HL60 cells (ATCC CCL 240) with blood cells from dogs challenged with field collected Ixodes scapularis ticks. After degenerative cell mo ⁇ hology becomes noticeable, the infected cells are passed over fresh uninfected HL60 cells to maintain the culture. USG3 is grown in RPMI 1640 containing 10-20% heat-inactivated fetal bovine serum, 2 mM 1-glutamine, 1 mM sodium pyruvate, 0.1 mM MEM non-essential amino acids and is split into fresh HL60 cells two to three times per week. This procedure is also outlined in Coughlin et al, PCT Application No. PCT/US96/10117 and has also been demonstrated by Goodman et al, N. Eng. J. Med. 334:209-215 (1996).
  • Protocol B GE Purification
  • USG3 cultures at approximately 80% cell lysis (monitored microscopically) are centrifuged at 840 x g for 15 min at 4°C to remove host HL60 cell debris.
  • the supernatant is filtered through a Poretics (Livermore, CA) 5 ⁇ m polycarbonate membrane, 47 mm in diameter, followed by a Poretics 3 ⁇ m filter under negative pressure.
  • the USG3 filtrate is centrifuged at 9460 x g in a Sorvall centrifuge for 30 min at 4°C. Following centrifugation, the GE pellet is resuspended in 5 ml 25 mM Tris, pH 8.0, 10 mM MgCl. and 0.9% NaCl.
  • DNasc I (Life Technologies, Gaithersburg, MD) is added to a final concentration of 9 ⁇ g per ml and the solution is incubated for 15 min at 37°C. Following incubation, the DNase is inactivated by the addition of 0.5 ml of 0.5 M EDTA and the GE is pelleted at 14,000 x g in a Sorvall centrifuge for 30 min at 4°C.
  • Genomic DNA is isolated from purified GE using the QIAamp Genomic DNA kit (Qiagen, Chatsworth, CA) for library preparation (Stratagene, La Jolla, CA). The DNA is mechanically sheared to a 4-10kb size range and ligated to EcoRI linkers. Linkered fragments are ligated into the EcoRI site of Lambda Zap II and the library is amplified in E. coli strain XLl-Blue MFR' to a titer of 10 10 Pfu/ml.
  • Protocol D Preparation of the Screening Sera Dog sera: Adult Ixodes scapularis ticks collected from regions of the eastern United
  • Goat sera Mixtures of 100 ⁇ g of purified heat-inactivated USG3 antigen are used to immunize goats. Goafs receive three subcutaneous doses of antigen at bi-weekly intervals. Serum is collected two weeks following the third immunization and is used for immunoscrecning of the GE genomic DNA library.
  • Protocol E Screening of the GE Genomic DNA library
  • Bacteriophage are diluted and plated with XL 1 -Blue MRF' cells on NZY agar plates. Plates are prepared giving approximately 50,000 plaques per plate. Phagcs are induced to express cloned protein with 10 mM IPTG (Sigma, St. Louis. Missouri) and transferred to nitrocellulose filters. For immunoscreening, filters are blocked in TBS (25mM Tris HC1, pH 7.5,0.5 M NaCl) containing 0.1% polyoxyethylene 20 cetyl ether (Brij 58) and incubated with pooled dog sera, pooled mouse sera, or pooled goat sera.
  • TBS 25mM Tris HC1, pH 7.5,0.5 M NaCl
  • Brij 58 polyoxyethylene 20 cetyl ether
  • the filters are washed and then reacted with anti-dog HRP conjugated antibody, anti-mouse HRP conjugated antibody, or anti- goat HRP conjugated antibody.
  • the filters are washed again and developed with 4- chloronapthol (Bio-Rad). Positive plaques are isolated, replated and rescreened twice to achieve purity. Plasmid
  • DNA containing the putative recombinant clones is obtained by plasmid rescue (Strategene, La Jolla, CA).
  • DNA sequencing and sequencing analysis DNA sequencing of recombinant clones was performed using the primer walking method and a DNA sequencer such as for example the ABI 373A DNA sequencer (ACGT, Northbrook, IL; Lark Technologies, Houston, TX; and Sequegen, Shrewsbury, MA). Sequences were analyzed by using the Mac Vector (Oxford Molecular Group) sequence analysis program, version 6.0, or the GCG package. The BLAST algorithm, D version 1.4, was used to search for homologous nucleic acid and protein sequences available on the National Center for Biotechnology Information (NCBI) server.
  • NCBI National Center for Biotechnology Information
  • DNA oligonucleotide primer sets are designed based on sequencing information from each individual clone. PCR primers were synthesized by standard oligonucleotide synthesis methods, or purchased for example from Life Technologies (Gaithersburg, MD). Templates for PCR are either purified plasmid DNA, purified GE or HL60 genomic DNA, genomic DNA isolated from infected blood or phage lysates. All reactions are performed using a Gene Amp 9600 thermal cycler (Perkin-Elmer, CT), GenAmp reagents from Perkin-Elmer, and TaqStart antibody (Clontech, CA).
  • the cycling program consists of 30 cycles, each of 30 s at 94 ° C, 30 s at 48 ° C to 55°C, and 1 min at 72°C, and an additional cycle of 10 min at 72 ° C.
  • some PCR amplification was carried out using nested reactions as described by Massung et al, J. Clin. Micro. 36: 1090 (1998). PCR products were analyzed on 4% Nusicve 3:1 agarose gels (FMC Bioproducts, Rockland, ME).
  • Protocol G Protein Isolation and Analysis
  • Overnight cultures of individual clones are diluted 1:25 into TP broth (per liter: 20 g bactotryptone, 2 g Na 2 HPO 4 , 1 g KH 2 PO 4 , 8 g NaCl, 15 g yeast extract) and grown at 37 °C until an OD 600 of 0.5 to 1 is reached. A 1.5 ml aliquot of culture is harvested. IPTG is added to a concentration of 5 mM and growth is continued for 3 hours at 37°C. The OD 600 is read and each culture is pelleted.
  • Pellets are resuspended in 5X Laemmli buffer (12% glycerol, 0.2 M Tris-HCl, pH 6.8, 5% SDS, 5% ⁇ -mercaptoethanol) at 200 ⁇ l per 1 OD unit.
  • harvested GE protein preparations are pelletted and resuspended in 0.4% SDS, 12.5 mM Tris, pH 6.8 and heated at 90-100°C for 20 min.
  • 50 ⁇ l of a cocktail consisting of RNase (33 ⁇ g/ml) and aprotinin (0.2 mg/ml) and 9 ⁇ l of DNase (0.17 mg/ml) is added per 5 mg of GE.
  • GE types found in the blood of three infected animals one dog, one horse, and a cow
  • ten humans four patients from Wisconsin, three patients from New York, one patient from Sweden, and two patients from Slovenia
  • S2 the GE160 nucleotide sequence of USG3 isolated from the blood of an experimentally infected dog
  • nested primer sets were designed to encompass the entire coding region.
  • Figure 1 shows the location of the primer sets (AQU1 (SEQ ID NO:27) and AQ1R2 (SEQ ID NO:28); AQU2 (SEQ ID NO:29) and AQ1R1 (SEQ ID NO:30); AQIF (SEQ ID NO:31) and AQIR (SEQ ID NO:32); AQ2F (SEQ ID NO:33) and AQ2R (SEQ ID NO:34); AQ3F (SEQ ID NO:35) and AQ3R (SEQ ID NO:36); AQ4F (SEQ ID NO:37) and AQ4R (SEQ ID NO:38); AQ4F1 (SEQ ID NO:39) and AQ4R1 (SEQ ID NO:40); AQ4F2 (SEQ ID NO:41) and AQD2 (SEQ ID NO:42); and AQ4F3 (SEQ ID NO:43) and AQD1 (SEQ ID NO:44)) and the corresponding PCR amplified fragments obtained.
  • the primer sets shown in Table 2 were used to amplify regions of the listed GE clones WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2.
  • Each oligonucleotide sequence is shown in the 5' to 3' orientation.
  • Figure 2 shows the alignment of the DNA sequence of all thirteen amplified GE160 genes compared to the S2 G160 gene (identified on the second line of the alignment as USG3).
  • Each 50 ⁇ l reaction contained 0.5 ⁇ M of each primer, IX PCR Supermix (Life Technologies, Gaithersburg, MD) and 2 ⁇ l of blood mix corresponding to approximately 100 ng of DNA prepared from the individual blood samples. PCR amplification was performed as described in Protocol F.
  • AQIF ATGTTACGCTGTAATAGCATGGAC
  • AQIR TGCCCCAGCTTCTACAACAC
  • AQ2F TCTCCAGAACCAGCTATTAC
  • AQ2R GAGTATTAAGCAAGTCTCCG
  • AQ3F GTCTCGAAAGCATTTGTCAAAC
  • AQ3R TTTCTCCCTTAGATGACGCC
  • AQ4F GAGCTGCAATTACTTCCGAG
  • AQ4R CTACCGCGACCTCCTTTTAC
  • AQ4F1 GCTGCAATTACTTCCGAGGC
  • AQ4R1 GCGACCTCCTTTTACAGACTTAG
  • AQ4F2 TGCTCCGGATTCTACCAAAG AQD2: GCCTAAATACTCAGAAGCGCGCG
  • AQ4F3 AAGGAACTAACAAAAGCTCC
  • AQD1 TATTGATCAAAGTACCTCAGCG
  • the primer pairs were used in separate PCR reactions to amplify the GE160 nucleotide sequence in the blood of three infected animals (one dog, one horse, and a cow) and ten humans (four patients from Wisconsin, three patients from New York, one patient from Sweden, and two patients from Slovenia).
  • An aliquot from each PCR reaction was run on a 1% agarose gel and stained with Ethidium Bromide to ascertain the approximate size of the PCR amplified fragment. In most cases the size of the PCR product matched the expected size based on the nucleotide sequence of S2 (data not shown). In some samples the PCR product fragments were found to contain deletion spanning nucleotides (1438-1518) corresponding to the deletion of the nucleotide encoding an entire 27 amino acid repeat.
  • the deduced amino acid sequences of all thirteen clones are shown in Figures 16-28.
  • the deduced amino acid sequences of the representative clones are as follows: one dog (designated WIC; see Figure 16), one horse (designated EQ; see Figure 18), a cow (designated BOV; see Figure 19) and ten humans, including four patients from Wisconsin (designated WIl, WI2, WI3, WI4; see Figures 20-23, respectively), three patients from New York (designated NYl, NY2, NY3; see Figures 24-26), one patient from Sweden (designated SWED; see Figure 17), and two patients from Slovenia (designated SLOVl and SLOV2; see Figures 27-28).
  • the alignment of the derived amino acid sequences from all thirteen GE clones have been compared to the amino acid sequence of the S2 GE160 protein as shown in Figure 29.
  • the HL60 cell lines infected with the GE isolates of the present invention are obtained by co-culturing HL60 cells (ATCC CCL 240) with blood cells from various animals and patients, as follows: one dog (designated WIC), one horse (designated EQ), a cow (designated BOV), and ten humans (four patients from Wisconsin (designated WIl, WI2, WI3, WI4), three patients from New York (designated NYl, NY2, NY3), one patient from Sweden (designated SWED) and two patients from Slovenia (designated SLOVl and SLOV2)). After degenerative cell morphology becomes noticeable, the infected cells are passed over fresh uninfected HL60 cells to maintain the culture.
  • GE is then grown in RPMI 1640 containing 10-20% heat- inactivated fetal bovine serum, 2 mM 1-glutamine, 1 mM sodium pyruvate, 0.1 mM MEM non-essential amino acids and is split into fresh HL60 cells two to three times per week. This procedure is also outlined in Coughlin et al, PCT Application No. PCT/US96/10117 and has also been demonstrated by Goodman et al, N. Eng. J. Med. 334:209-215 (1996).
  • the 16S ribosomal genes are amplified and analyzed as follows.
  • Cell extracts are prepared by lysis protocols as described supra.
  • PCR primers (specific for the 16S ribosomal DNA) are modified to include restriction enzyme recognition sites as follows:
  • forward primer 5'-CTGCAGGTTTGATCCTGG-3' (Pstl site) (SEQ ID NO:45); reverse primer, 5'-GGATCCTACCTTGTTACGACTT-3' (BamHI site)(SEQ ID NO:46).
  • Protocol B from the above cultures is purified according to Protocol B and a genomic library is constructed according to Protocol C.
  • the library is screened using sera prepared as in Protocol D or derived from the blood of different infected animals or patients as discussed. Screening is performed as in Protocol E.
  • the identified clones are then purified as single plaques by a third immunoscreening. Plasmids are rescued according to the Stratagene protocol and DNA purified using Qiagen plasmid purification kits. Single enzyme digests are then performed with EcoRI, Hindlll, BamHI, Hindi, Xbal, Pstl and Alw26I and in some cases a number of double digests may be done. Based on these digests restriction maps are generated and compared to that deduced on the basis of the PCR derived nucleotide sequences of Example 1.
  • PCR primer sets are as described in Table 2. The sequences of each primer set indicated in Table 2 are used to amplify regions of the listed clones WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2. Each oligonucleotide sequence is shown in the 5' to 3' orientation.
  • Each 50 ⁇ l reaction contained 0.5 ⁇ M of each primer, IX PCR Supermix (Life Technologies, Gaithersburg, MD) and 100 ng of either purified GE DNA of the various types of 6E (WIl, WI2, WI3, WI4, WIC, NYl, NY2, NY3, SWED, BOV, EQ, SLOVl, and SLOV2), 100 ng HL60 DNA or 200 ng plasmid DNA.
  • PCR amplification is performed as described in Protocol F.
  • the isolated clones arc induced to express the encoded protein and bacterial extracts are prepared for SDS-PAGE as outlined in Protocol G.
  • SDS-PAGE and Western blot analysis (using SDS-disrupted whole GE as a positive control and a non-protein expressing clone as a negative control) is expected to identify immunoreactive proteins for each clones using sera as described in Protocol D.
  • the same proteins are expected to be detectable when probed with sera obtained form human patients with GE. Based on the amino acid sequences of these proteins, the calculated molecular weights are expected to be significantly lower than the apparent molecular weights by SDS-PAGE.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne, de façon générale, des protéines d'ehrlichia granulocyte (GE). En particulier, l'invention concerne des molécules d'acide nucléique codant pour des protéines WI1, WI2, WI3, WI4, WIC, NY1, NY2, NY3, SWED, BOV, EQ, SLOV1 et SLOV2; des protéines et polypeptides purifiés WI1, WI2, WI3, WI4, WIC, NY1, NY2, NY3, SWED, BOV, EQ, SLOV1 et SLOV2; des molécules d'acide nucléique recombinantes; des cellules contenant les molécules d'acide nucléique recombinantes; des anticorps ayant une affinité de liaison spécifiquement avec des protéines et polypeptides WI1, WI2, WI3, WI4, WIC, NY1, NY2, NY3, SWED, BOV, EQ, SLOV1 et SLOV2; des hybridomes contenant les anticorps; des sondes d'acide nucléique pour la détection des acides nucléiques codant pour des protéines WI1, WI2, WI3, WI4, WIC, NY1, NY2, NY3, SWED, BOV, EQ, SLOV1 et SLOV2; un procédé de détection d'acides nucléiques codant pour des protéines ou polypeptides WI1, WI2, WI3, WI4, WIC, NY1, NY2, NY3, SWED, BOV, EQ, SLOV1 et SLOV2 dans un échantillon; des kits contenant des sondes d'acide nucléique ou des anticorps; des biotests utilisant la séquence acide nucléique, les protéines ou anticorps de l'invention pour des diagnostics, estimations ou pronostics chez un mammifère atteint d'ehrlichiose; des utilisations thérapeutiques, en particulier des vaccins comprenant des protéines, des polypeptides ou des acides nucléiques; ainsi que des procédés pour la prévention ou l'inhibition d'ehrlichiose chez un animal.
EP98955088A 1998-07-28 1998-10-23 Genes d'ehrlichia granulocyte et leurs utilisations Withdrawn EP1100917A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9438198P 1998-07-28 1998-07-28
US94381P 1998-07-28
PCT/US1998/022512 WO2000006744A1 (fr) 1998-07-28 1998-10-23 Genes d'ehrlichia granulocyte et leurs utilisations

Publications (1)

Publication Number Publication Date
EP1100917A1 true EP1100917A1 (fr) 2001-05-23

Family

ID=22244840

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98955088A Withdrawn EP1100917A1 (fr) 1998-07-28 1998-10-23 Genes d'ehrlichia granulocyte et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1100917A1 (fr)
JP (1) JP2002527042A (fr)
AU (1) AU1197799A (fr)
CA (1) CA2340855A1 (fr)
WO (1) WO2000006744A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330393T3 (es) 1997-04-25 2009-12-09 Antigenics Inc. Caracterizacion de ehrlichia granulocitica y metodos de uso.
US9133525B2 (en) 2012-01-26 2015-09-15 Luc Montagnier Detection of DNA sequences as risk factors for HIV infection
US9651546B2 (en) 2012-10-11 2017-05-16 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976860A (en) * 1995-06-06 1999-11-02 Aquila Biopharmaceuticals, Inc. Cell lines infected with granulocytic ehrlichia, vaccines, diagnostics and methods
US6015691A (en) * 1996-05-31 2000-01-18 Research Development Foundation Immunodominant 120 kDa surface-exposed adhesion protein genes of Ehrlichia chaffeensis
US6207169B1 (en) * 1997-03-21 2001-03-27 Corixa Corporation Compounds and methods for the diagnosis and treatment of Ehrlichia infection
ES2330393T3 (es) * 1997-04-25 2009-12-09 Antigenics Inc. Caracterizacion de ehrlichia granulocitica y metodos de uso.
EP0915979A2 (fr) * 1997-04-25 1999-05-19 Aquila Biopharmaceuticals, Inc. Acides nucleiques, proteines et modes d'utilisation d'erhlichia granulocyte

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0006744A1 *

Also Published As

Publication number Publication date
WO2000006744A1 (fr) 2000-02-10
CA2340855A1 (fr) 2000-02-10
JP2002527042A (ja) 2002-08-27
AU1197799A (en) 2000-02-21

Similar Documents

Publication Publication Date Title
US8435495B2 (en) Characterization of granulocytic Ehrlichia and methods of use
AU734659B2 (en) Nucleic acids, proteins, and methods of use of granulocytic erhlichia
US9861690B2 (en) Ehrlichia ewingii proteins, nucleic acids, and methods of their use
EP1108014A1 (fr) PROTEINE ANTIGENIQUE IMMUNODOMINANTE DE 120 KDA D'$i(EHRLICHIA CANIS) ET GENE AFFERENT
CA2294568A1 (fr) Vaccins contre la maladie de lyme
WO1997027301A9 (fr) Compositions de proteines de liaison de la decorine et modes d'utilisation
EP0877808A1 (fr) Compositions de proteines de liaison de la decorine et modes d'utilisation
US6669940B2 (en) Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof
WO2000006744A1 (fr) Genes d'ehrlichia granulocyte et leurs utilisations
US20040047871A1 (en) Recombinant fusobacterium necrophorum leukotoxin vaccine and prepaation thereof
AU704821B2 (en) New 17-KDA brucella abortus antigen, recombinant polypeptides, nucleic acids coding for the same and use thereof in diagnostic and prophylactic methods and kits
JPH10313875A (ja) 新規化合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030503